Literature DB >> 1711186

HMB-45 immunohistochemical staining of conjunctival melanocytic lesions.

J M McDonnell1, Y Y Sun, D Wagner.   

Abstract

HMB-45 is a monoclonal antibody recently described as being highly specific for melanocytic proliferations of the skin and in metastases of melanotic lesions. To determine a possible role for HMB-45 in ophthalmic pathology, 45 conjunctival lesions, including 23 melanomas, were analyzed using immunohistochemical techniques with anti-S-100 and HMB-45 as primary antibodies. Nineteen (82.6%) of the melanomas exhibited HMB-45 positivity, and 19 (82.6%) contained S-100 protein, with concordance of all but two cases. Seven cases of primary acquired melanosis were studied; one (33%) of three with atypia was HMB-45 positive, as were two (50%) of four without atypia. Among nevi, 1 (9.1%) of 11 showed faint staining with HMB-45. Fifteen conjunctival epithelial dysplasias were negative with HMB-45. At present, HMB-45 appears to offer no great advantage over S-100 protein in the analysis of conjunctival melanomas. Its role in the distinction of benign from atypical or malignant junctional melanocytic proliferations remains unclear.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1711186     DOI: 10.1016/s0161-6420(91)32281-4

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  3 in total

1.  Immunophenotypic markers to differentiate between benign and malignant melanocytic lesions.

Authors:  S Keijser; G S Missotten; J M Bonfrer; D de Wolff-Rouendaal; M J Jager; R J W de Keizer
Journal:  Br J Ophthalmol       Date:  2006-02       Impact factor: 4.638

2.  Novel multiple markers to distinguish melanoma from dysplastic nevi.

Authors:  Guohong Zhang; Gang Li
Journal:  PLoS One       Date:  2012-09-27       Impact factor: 3.240

3.  Conjunctival melanoma: a review of conceptual and treatment advances.

Authors:  Li-Anne Lim; Michele C Madigan; R Max Conway
Journal:  Clin Ophthalmol       Date:  2013-03-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.